These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29650809)

  • 1. [Molecular Targeted Therapies for Hereditary Cancer Syndrome].
    Shimodaira H
    Gan To Kagaku Ryoho; 2018 Apr; 45(4):587-592. PubMed ID: 29650809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Specific features of drug sensitivity of hereditary cancers].
    Imyanitov EN
    Vopr Onkol; 2016; 62(2):221-6. PubMed ID: 30452211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized Systemic Therapies in Hereditary Cancer Syndromes.
    Mastrodomenico L; Piombino C; Riccò B; Barbieri E; Venturelli M; Piacentini F; Dominici M; Cortesi L; Toss A
    Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current status of PARP inhibitors in ovarian cancer.
    McLachlan J; George A; Banerjee S
    Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
    McCann KE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic testing by cancer site: ovary.
    Weissman SM; Weiss SM; Newlin AC
    Cancer J; 2012; 18(4):320-7. PubMed ID: 22846732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leveraging DNA repair deficiency in gynecologic oncology.
    Walsh CS; Hodeib M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):24-31. PubMed ID: 26694829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRACAnalysis CDx as a companion diagnostic tool for Lynparza.
    Gunderson CC; Moore KN
    Expert Rev Mol Diagn; 2015; 15(9):1111-6. PubMed ID: 26292709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory PARP w terapii raka jajnika.
    Kruczała MA; Grela-Wojewoda A; Cedrych I
    Ginekol Pol; 2016; 87(2):131-4. PubMed ID: 27306290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic testing for cancer predisposition.
    Eng C; Hampel H; de la Chapelle A
    Annu Rev Med; 2001; 52():371-400. PubMed ID: 11160785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Next-Generation Sequencing for Hereditary Cancer Syndromes: A Focus on Lynch Syndrome and Associated Endometrial Cancer.
    Tafe LJ
    J Mol Diagn; 2015 Sep; 17(5):472-82. PubMed ID: 26162329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
    Domagala P; Hybiak J; Cybulski C; Lubinski J
    Int J Cancer; 2017 Apr; 140(7):1545-1550. PubMed ID: 27943282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
    Dulaney C; Marcrom S; Stanley J; Yang ES
    Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
    Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
    Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic testing and prevention of hereditary cancer at the MMCI--over 10 years of experience.
    Foretova L; Petrakova K; Palacova M; Kalabova R; Svoboda M; Navratilova M; Schneiderova M; Bolcak K; Krejci E; Drazan L; Mikova M; Hazova J; Vasickova P; Machackova E
    Klin Onkol; 2010; 23(6):388-400. PubMed ID: 21348412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.
    Colicchia V; Petroni M; Guarguaglini G; Sardina F; Sahún-Roncero M; Carbonari M; Ricci B; Heil C; Capalbo C; Belardinilli F; Coppa A; Peruzzi G; Screpanti I; Lavia P; Gulino A; Giannini G
    Oncogene; 2017 Aug; 36(33):4682-4691. PubMed ID: 28394338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical genetics of hereditary colorectal cancer.
    Power DG; Gloglowski E; Lipkin SM
    Hematol Oncol Clin North Am; 2010 Oct; 24(5):837-59. PubMed ID: 20816577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.
    Wang Z; Qian H; Yiu SM; Sun J; Zhu G
    J Inorg Biochem; 2014 Feb; 131():47-55. PubMed ID: 24239912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the recognition and management of hereditary cancer.
    Kulkarni A; Carley H
    Br Med Bull; 2016 Dec; 120(1):123-138. PubMed ID: 27941041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.